Search

Your search keyword '"D'Antiga, L."' showing total 27 results
Start Over Author "D'Antiga, L." Journal journal of pediatric gastroenterology & nutrition
27 results on '"D'Antiga, L."'

1. Maralixibat-treated patients with Alagille syndrome (ALGS) demonstrate improved event-free survival in a natural history comparison with patients from the GALA database: application of real-world evidence analytics.

Author

Hansen, B. E., Vandriel, S. M., Vig, P., Garner, W., Li, L.-T., She, H., Wang, J.-S., Gilbert, M. A., Jankowska, I., Czubkowski, P., Gliwicz-Miedzińska, D., Gonzales, E. M., Jacquemin, E., Bouligand, J., Spinner, N. B., Loomes, K. M., Piccoli, D. A., D'Antiga, L., Nicastro, E., and Sokal, É.

Published
2022
Full Text
View/download PDF

3. Analysis of quality of life, hepatic biochemical markers, and sleep in patients with progressive familial intrahepatic cholestasis who had a pruritus response with odevixibat treatment.

Author

Gupte, G., Thompson, R. J., D’Antiga, L., Grammatikopoulos, T., Gonzalès, E., Lacaille, F., Lachaux, A., Roquelaure, B., Baumann, U., Lainka, E., Sturm, E., Shteyer, E., Czubkowski, P., Artan, R., Dalgic, B., Özen, H., Loomes, K. M., Vittorio, J. M., Karpen, S. J., and McKiernan, P.

Published
2022
Full Text
View/download PDF

20. Titration of Bile Acid Supplements in 3ß-Hydroxy-?5-C27-Steroid Dehydrogenase/Isomerase Deficiency

Author

Riello, L, D'Antiga, L, Guido, M, Alaggio, R, Giordano, G, and Zancan, L

Abstract

3ß-Hydroxy-?5-C27-steroid dehydrogenase/isomerase deficiency is a bile acid synthesis defect responsive to primary bile acids. We reviewed its clinical features and response to treatment with a mixture of ursodeoxycholic (UDCA) and chenodeoxycholic acid (CDCA) to titrate the dose of supplements required for disease control. We studied our patients by liquid chromatography-tandem mass spectrometry, liver function tests, and histology. After diagnosis all of the patients received a balanced mixture of UDCA/CDCA and the dose was titrated according to urinary levels of 3ß,7a-dihydroxy-5-cholenoic acid (u-3ß-D-OH-5C). Five patients presenting with giant cell hepatitis, biliary cirrhosis, and cryptogenic cirrhosis (1 each), and picked up by neonatal screening (2 patients) were diagnosed at a median age of 2.5 years (range 0.1–5.5). Normal levels of u-3ß-D-OH-5C were achieved after 4 months (range 3–28 months) from the start of the treatment. The minimum dose of UDCA/CDCA required to maintain normal u-3ß-D-OH-5C levels was 5/5 mg · kg-1· day-1. A follow-up biopsy in 2 patients showed no progression of liver disease. A mixture of UDCA/CDCA can effectively control 3ß-hydroxy-?5-C27-steroid dehydrogenase/isomerase deficiency. Dose titration by liquid chromatography-tandem mass spectrometry warrants the maintenance of negative feedback on the abnormal synthetic pathway and avoids disease progression.

Published
2010
Full Text
View/download PDF

27. Early and Late Factors Impacting Patient and Graft Outcome in Pediatric Liver Transplantation: Summary of an ESPGHAN Monothematic Conference

Author

Stefan G. Hubscher, Sandy Feng, Vincent Karam, Stephen Gottschalk, Anil Dhawan, Pietro Vajro, Raymond Reding, Dominique Debray, Nedim Hadzic, Valérie A. McLin, Valerio Nobili, Christian Toso, Khalid Sharif, Ozlem Durmaz, Stéphanie Franchi-Abella, Deirdre Kelly, Michele Colledan, Funda Ozgenc, Ulrich Baumann, Patrick J. McKiernan, Rainer Ganschow, Barbara E. Wildhaber, Anita Verma, Lorenzo D'Antiga, Loreto Hierro, George V. Mazariegos, Marco Sciveres, John C. Bucuvalas, Jean de Ville de Goyet, Christine S. Falk, Simon Horslen, Anette Melk, Maria-Cristina Cuturi, Antal Dezsofi, Olivia Boyer, Upton Allen, Esteban Frauca, Britta Maecker-Kolhoff, Piotr Socha, Björn Fischler, Mclin, V, Allen, U, Boyer, O, Bucuvalas, J, Colledan, M, Cuturi, M, D'Antiga, L, Debray, D, Dezsofi, A, de Goyet, J, Dhawan, A, Durmaz, O, Falk, C, Feng, S, Fischler, B, Franchi-Abella, S, Frauca, E, Ganschow, R, Gottschalk, S, Hadzic, N, Hierro, L, Horslen, S, Hubscher, S, Karam, V, Kelly, D, Maecker-Kolhoff, B, Mazariegos, G, Mckiernan, P, Melk, A, Nobili, V, Ozgenc, F, Reding, R, Sciveres, M, Sharif, K, Socha, P, Toso, C, Vajro, P, Verma, A, Wildhaber, B, and Baumann, U

Subjects
Graft Rejection, medicine.medical_specialty, Tissue and Organ Procurement, research goal, medicine.medical_treatment, complication, 030230 surgery, Liver transplantation, Pediatrics, Drug Administration Schedule, 03 medical and health sciences, Postoperative Complications, 0302 clinical medicine, Outcome Assessment, Health Care, Humans, Medicine, Child, Intensive care medicine, Donor pool, Settore MED/38 - Pediatria Generale e Specialistica, ddc:618, tolerance, liver transplantation, business.industry, Graft Survival, Gastroenterology, Immunosuppression, pediatric, Pediatrics, Perinatology and Child Health, Quality of Life, 030211 gastroenterology & hepatology, business, Immunosuppressive Agents
Abstract

As pediatric liver transplantation comes of age, experts gathered to discuss current paradigms and define gaps in knowledge warranting research to further improve patient and graft outcomes. Identified areas ripe for collaborative research include understanding the molecular and cellular mechanisms of tolerance and the role of donor-specific antibodies, considering ways to expand donor pool, minimizing long-term side effects of immunosuppression, and fine-tuning surgical techniques to minimize biliary and vascular complications. Copyright © 2017 by European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results